Keith Carter News
Most Popular Keith Carter Story
Allergy Therapeutics afflicted by FDA's move to halt trials
Shares of Allergy Therapeutics tumbled 22 percent after the FDA froze two late-stage studies of a hayfever vaccine after one of the volunteers in a trial fell ill. The patient reported neurological Read more...
Latest Headlines
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
